Aptamer expands odour control collaboration with Unilever

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has announced the signing of a second Optimer discovery and development programme with global consumer goods leader, Unilever.

Under the new agreement, Aptamer will develop a novel panel of Optimer binders targeting an additional biological pathway associated with body odour formation, potentially providing Unilever with a second strategy to prevent the formation of body malodour. The agreement is structured on a fee-for-service basis, with Aptamer receiving an undisclosed six-figure sum for the development work.  

This new programme builds on the success of the initial programme, which focused on inhibiting a key bacterial enzyme involved in body odour production. Optimers from the initial programme have passed internal validation and lab-based testing, both at Aptamer and Unilever, with on-person performance trials anticipated in 2025.

Unilever commands over 30 per cent of the global deodorant market, compared to 10 per cent for its nearest competitor. With the sector expected to grow at a CAGR of 4.5 per cent over the next five years, the commercial opportunity for Aptamer in personal care is significant. This collaboration highlights the scalability and cross-sector potential of the Optimer platform, traditionally applied in therapeutic and diagnostic markets, and now entering the high-volume consumer health space.

Dr Arron Tolley, Chief Executive Officer, Aptamer Group, said: “I am excited by the additional project we are undertaking with Unilever. This project expands our partnership with Unilever in the odour control space. The excellent results produced by our team in the first project have resulted in a deepening partnership with Unilever, expanding on the applicability of our Optimer binders.

“The first project is now moving toward on-person trials, and this deal positions us well to create multiple, licensable assets with a global powerhouse in the consumer health market. This second programme reflects the confidence Unilever has in the Optimer platform and the significant value we can unlock by expanding our offering into novel, large-scale applications like personal care.”

Dr Sam Samaras, Senior Vice President R&D, Unilever, said: “This new project with Aptamer Group reflects the positive nature of the collaboration thus far. This was the first time that Unilever has examined Optimer binders in cosmetic applications and the data so far have shown encouraging results. We have agreed on a follow up project targeting novel approaches for odour control using Optimer technology. We will continue to engage with the world class team at Aptamer Group to explore this and additional opportunities.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

    Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event.

    Aptamer signs contract with Metir for Cryptosporidium detection binders

    Aptamer has signed a new contract with Metir plc to develop Optimer® binders for the rapid detection of Cryptosporidium parvum oocysts in Metir’s Pathogen Detector platform.

    Aptamer signs therapeutic development deal with Invizius

    Aptamer Group has entered a new agreement with Invizius to develop Optimer® binders targeting the complement system for inflammatory and autoimmune diseases. The collaboration aims to enhance Invizius’ H-Guard® platform, currently in Phase 2 trials, by providing safer and more precise therapies, including potential treatments for IgA nephropathy.

    Aptamer advances enzyme modulation projects and expands pharma collaboration

    Aptamer Group announced progress on its Optimer® enzyme modulation projects, including a 10-year non-exclusive licensing deal forecast to cover around 15% of annual overheads and further agreements under discussion with global enzyme distributors.

    Aptamer secures contract Eetension with top 5 pharma partner

    Aptamer has extended its collaboration with a top 5 global pharmaceutical company to advance Optimer® binders into a fully functional ELISA assay. The agreement builds on the successful completion of the initial binder development phase, with Aptamer retaining IP ownership to support future commercialisation opportunities.

    Aptamer Group to host technical development update webinar

    Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes.

      Search

      Search